FEATURE
INFOGRAPHIC
Circulating tumor cells survey infographic
As part of this Spotlight on CTCs, we were keen to discover the thoughts of our audience concerning the current applications of CTCs and their potential future adoption in the clinic. We had a great response to our survey and the results have been translated into this summary infographic. Click on the image below to view this in full.
Circulating tumor cells 8
Europe 53%
North America 25%
11%Asia 38.6%
University/College 10.5%
11% Rest of the world
Managing Director/CEO Practicing clinician
7% 29.8%
Academic 19.3%
CTCs in your organization
Are you yourself or your institution involved in the research and development of liquid biopsy techniques?
Not sure 4.5% No 30.3% Yes 65.2% 51% of respondents suggested that CTCs are
an area of PRIORITY within their institution
Researcher 33.3%
Student 3.5%
Other ?7% 5.3%
Pharmaceutical/ Biotechnology
40.4%
Research Lab/Institution/ Foundation
Hospital/Medical Center/ Clinic
?
5.3% Other
Current status of CTCs for liquid biopsy
www.oncology-central.com Within liquid biopsy, which sample category do you think currently holds the most potential?
ou yourself o
the research and de biopsy techniques?
Not sure 4.5% No 30.3%
Current status of CTCs for Within liquid biopsy, which sample category do you
In which areas do you think CTCs currently hold the most clinical value Early diagnosis of cancer, screening and detection of recurrence
Personalizing therapy to an individual’s disease Prediction of therapy response Predicting patient prognosis
Monitoring response to therapy over time and development of resistance
Elucidation and monitoring of the metastatic process Other
37.3% 3.4% What do you think are the biggest challenges in CTC research and utility? 42.4% 35.6% 25.4% 7
32.8%
Increasing sensitivity to detect low level or sub-clinical disease
50%
Availability of sensitive, standardized isolation platforms
29.3%
Need for improved enrichment techniques
34.5%
Obtaining a high-quality sample from a small volume
50%
Elucidating the relationship between CTCs and patient outcomes
31%
Determining the use and worth of CTCs across multiple tumor types
84.5% Bringing CTCs to the clinic
Key oncological disease areas in which respondents think CTC enumeration and molecular characterization could soon affect clinical practice:
58.2% Breast cancer 41.8% Metastatic disease
of respondents believe that there could
be a ROLE for CTCs within and CLINICAL TRIALS
DRUG DEVELOPMENT
43.6% Lung cancer
23.6% Prostate cancer
38.2% Colorectal cancer
In your opinion, what needs to be done to validate the use of CTCs in the clinic?
Are CTCs an area of priority within cancer research?
What could be the timeframe for adoption of CTCs as a key part of the clinical decision-making process?
10.5%
CTCs already have a key role in the clinic
49.1% Within the next 3 years
26.3% 5–10 years
1.8% 10+ years
12.3% Unable to say
View more of our spotlight content
Sign up to OC
x ~
Yes No
84.2% 3.5%
Not sure 12.3%
CTCs 20.3%
Extracellular vesicles 3.4%
Circulating RNAs 5.1%
Circulating free DNA 25.4%
Circulating tumor cells
Europe 53%
North America 25%
11%Asia 38.6%
University/College 10.5%
11% Rest of the world
Managing Director/CEO Practicing clinician
7% 29.8%
Academic 19.3%
CTCs in your organization
Are you yourself or your institution involved in the research and development of liquid biopsy techniques?
Not sure 4.5% No 30.3% Yes 65.2% 51% of respondents suggested that CTCs are
an area of PRIORITY within their institution
Researcher 33.3%
Student 3.5%
Other ?7% 5.3%
Pharmaceutical/ Biotechnology
40.4%
Research Lab/Institution/ Foundation
Hospital/Medical Center/ Clinic
?
5.3% Other
Current status of CTCs for liquid biopsy Within liquid biopsy, which sample category do you think currently holds the most potential?
In which areas do you think CTCs currently hold the most clinical value? Early diagnosis of cancer, screening and detection of recurrence
Personalizing therapy to an individual’s disease Prediction of therapy response Predicting patient prognosis
Monitoring response to therapy over time and development of resistance
Elucidation and monitoring of the metastatic process Other
37.3% 3.4% What do you think are the biggest challenges in CTC research and utility? 35.6% 25.4% 72.9%
55.9% 42.4%
32.8%
Increasing sensitivity to detect low level or sub-clinical disease
50%
Availability of sensitive, standardized isolation platforms
29.3%
Need for improved enrichment techniques
34.5%
Obtaining a high-quality sample from a small volume
50%
Elucidating the relationship between CTCs and patient outcomes
31%
Determining the use and worth of CTCs across multiple tumor types
84.5% Bringing CTCs to the clinic
Key oncological disease areas in which respondents think CTC enumeration and molecular characterization could soon affect clinical practice:
58.2% Breast cancer 41.8% Metastatic disease
of respondents believe that there could
be a ROLE for CTCs within and CLINICAL TRIALS
DRUG DEVELOPMENT
43.6% Lung cancer
23.6% Prostate cancer
38.2% Colorectal cancer
In your opinion, what needs to be done to validate the use of CTCs in the clinic?
Are CTCs an area of priority within cancer research?
x ~
What could be the timeframe for adoption of CTCs as a key part of the clinical decision-making process?
Yes No
84.2% 3.5%
Not sure 12.3%
10.5%
CTCs already have a key role in the clinic
49.1% Within the next 3 years
26.3% 5–10 years
1.8% 10+ years
12.3% Unable to say
View more of our spotlight content
Sign up to OC
Other 1.7%
All of equal importance 44.1%
Extracellular vesicles 3.4%
Circulating RNAs 5.1%
CTCs Circulating free DNA 20.3%
25.4%
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14
